 |
|
Dr. Kai-Uwe Bindseil, CEO,
BioTOP
Dr. Kai-Uwe Bindseil studied chemistry at Georg August University
in Göttingen. In 1993, he wrote his doctoral thesis in bioorganic
chemistry under the guidance of Prof. A. Zeeck. After a post-doctoral
fellowship at Ciba-Geigy AG in Basle, he moved to AnalytiCon in
1994, where he is currently responsible for drug discovery, marketing
and business development. As of mid-August he has become CEO of
BioTOP.
back
to top
|
 |
|
 |
|
Professor Graham John Boulnois,
Schroder
Ventures Life Sciences
Professor Graham John Boulnois joined Schroder Ventures
in August 2001.
Before joining Schroder Venture, Professor Boulnois
was senior vice president of Drug Innovation and Approval at Aventis
Pharma AG. Here he had global responsibility for lead generation
in biotechnology, screening, medical and synthetic chemistry, chemical
development and informatics, in addition to R&D portfolio management
as part of the senior R&D team. Prior to joining Aventis, Graham
spent a number of years at AstraZeneca Pharmaceuticals, latterly
as global vice president and head of enabling science and technology.
Graham has a BSc in biological science and a PhD
in molecular biology from the University of Leicester.
back
to top
|
 |
|
| |
|
Dr. Fredrik Buch, Partner,
HealthCap
Partner of HealthCap. Prior to joining Odlander Fredrikson
in 2000 he was at SEB Investment Management and supervised the SEB
Healthcare Fund. Dr Buch has senior management experience from pharmaceutical
companies Pharmacia-Upjohn as Head of Clinical Research and Biostatistics
in urology, gynecology and autoimmune diseases and as Medical Director
at Svenska Hoechst AB and Squibb Scandinavia. Dr Buch received his
medical training at the University of Gothenburg, where he also
served as Lecturer at the Institute of Anatomy. He is the author
of more than 25 scientific papers in the area of bone biology and
has trained as specialist in orthopedic surgery. In 1981 he became
a licensed doctor and in 1985 he published his thesis rendering
him a Ph.D. degree.
back
to top
|
 |
|
|
|
|
Kerry Clough
GlaxoSmithKline
Kerry joined Glaxo in 1994 and is currently Director, Business
Development in the Worldwide Business Development group of GlaxoSmithKline.
He has concluded a wide range of compound in-licensing, out-licensing
and research collaboration transactions with established and emerging
pharmaceutical corporations in Europe and the USA.
Prior to this he was responsible for developing
the global commercial strategy for RelenzaTM, GSK's treatment for
influenza, and for the antibiotics ZinnatTM and FortumTM.
Before joining Glaxo, Kerry was in Business Planning
for Kodak's diagnostic systems healthcare group and a Product Manager
for antibiotics, in the Middle East Region, with Eli Lilly.
Kerry has a BSc in Mathematics and Biology and an
MBA.
back
to top
|
 |
|
|
|
Prof. Dr. Kai Deusch, Director,
Apax Partners
Deusch started studying Biology and Medicine at the University
of Minnesota, Johannes Gutenberg University in Mainz and the University
of London in 1987. He received a PhD in Immunology from the Johannes
Gutenberg University in Mainz. After his residency in Internal Medicine
at the Dept. of Medicine of Johannes Gutenberg University he conducted
post-doctoral studies in molecular T cell immunology at Harvard
University, Boston and earned the Professor`s Degree in Internal
Medicine from the Technical University in Munich. Deusch joined
McKinsey and Company in 1996 as a member of European Leadership
Group in pharmaceuticals and healthcare. While at McKinsey he also
co-founded its New Venture Practise, advising young companies in
diverse life science and healthcare businesses. In Spring 1999 he
founded Medicis, a life science focussed venture capital company
investing in early stage companies. Kai Deusch joined the healthcare
team of Apax Partners in June 2001.
back
to top
|
 |
|
| |
|
Prof. Dr. Horst Domdey, CEO,
Bio-M AG
As well as holding the position of Managing Director & CEO
at Bio-M AG, Prof. Dr. Horst Domdey is also Managing Director of
the Innovation Centre for Biotechnology (IZB), Chairman of the Munich
BioRegio Initiative and Co-founder of MediGene AG and Switch Biotech
AG. He has vast experience in the field of Biochemistry having been
a Postdoctoral fellow at numerous institutes including Max-Planck-Institut
fur Biochemie, the Swiss Institute for Experimental Cancer Research
(ISREC), University of California and the California Institute of
Technology. Further to this, he was Associate Professor for Biochemistry
at the Ludwig-Maximilians-Universitat Munchen for 4 years.Inc.
back
to top
|
 |
|
| |
|
Dr. Alexandra Goll, Partner,
TVM Techno Venture Management
Dr. Goll came to TVM in February of 1998. She represents the interests
of TVM at Actelion Ltd. (Allschwil, CH) and serves on the Board
of Axxima Pharmaceuticals AG (Martinsried), Cardion AG (Erkrath),
Curacyte AG(Munich), Migragen AG (Tübingen), Novirio Pharmaceuticals
Inc. (Cambridge,MA), Pharmasset Ltd. (Bridgetown, Barbados) and
Zeptosens AG (Witterswil, CH). Prior to her affiliation with TVM,
Dr. Goll was the Global Business Leader for HIV and CMV, and was
responsible for strategic marketing and business development for
Virology at Hoffmann-La Roche in Basel. She holds a degree in pharmacy
from the Free University of Berlin, and wrote her doctoral dissertation
in natural sciences at Philipps University of Marburg. She was honoured
with a post-doctoral position supported by the Boehringer-Ingelheim
Foundation for fundamental research in medicine.
back
to top
|
 |
|
| |
|
Dr. Rudolf Gygax, Portfolio & Business
Manager,
Novartis Venture Fund
Dr. Rudolf Gygax studied Physical Chemistry at the University of
Basel and Stanford University and joined Ciba-Geigy AG in 1978,
where he held various positions in the management of R&D, dealing
with Process Safety and Materials Research. Since 1997 he is the
Portfolio & Business Manager ofthe Novartis Venture Fund
back
to top
|
 |
|
| |
|
Barbara Heller, First Vice President,
Bank Vontobel
AG
Barbara Heller joined Bank Vontobel AG in 1997. Since then
she was the responsible project manager of several international
public offerings such as Gretag Imaging (SWX/144A), United Internet
(Neuer Markt), MediGene (Neuer Markt/144A), Private Equity Holding
(SWX Investment Company/144A) and other equity transactions including
M&A and Secondary transactions. Before joining Bank Vontobel
AG, Barbara Heller worked in different areas of the international
capital markets and was head of Corporate Finance / Financial Engineering
of another Swiss private bank in Zurich. Barbara Heller graduated
in economics at the University of Zurich (MBA).
back
to top
|
 |
|
|
|
|
Andreas Hoffmann, Partner,
Baker & McKenzie
Dr. Andreas Hoffmann LL.M. has been partner at Baker & McKenzie
in Munich since April 2001. After being admitted to the Bar in 1993,
he was Attorney at Döser Amereller Noack until 1995. From 1995
Dr. Hoffmann served as in-house Counsel (international corporate
law) at BMW AG in Munich, and from 1999 – 2000 he was General
Counsel for mg technologies AG. He subsequently served on the Management
Board of Advanced Medien AG until his current appointment at Baker
& McKenzie, Munich.
Dr. Hoffmann studied law at the universities of Wuerzburg and Freiburg,
and received his Master of Law from the University of Miami in 1995.
Dr. Andreas Hoffmann specialises in the areas of Private Equity,
Venture Capital, M & A and general corporate law.
back
to top
|
 |
|
|
|
Dr. Jens A. Katzek, Managing Director,
German Association of Biotechnology
Industries (DIB)
Dr. Jens Katzek, 38, biochemist by education and since March 2001
Managing Director of the German Association of Biotechnology Industries
(DIB).
During his professional career he was working
in different positions on the regulation and public debate of genetic
engineering. He was working as an Scientific advisor of the European
Commission, the personal assistant of Edelgard Buhlman, Member of
Parliament, now Minister for Research in Germany, and an environmental
organisation. During the last four years he was Head of Communication
for the company KWS Seed AG.
back
to top
|
 |
|
| |
|
Dr. Hans A Küpper, Managing Director,
Life Science Ventures GmbH
Dr. Küpper received his PhD from the University of Heidelberg.
He joined Biogen, Geneva, in 1980 where he held various positions,
last as Assistant Research Director. In 1985, he joined Behringwerke
AG where he was heading large R&D units and at a later stage
was increasingly involved in company restructurings like acqusitions,
spin-offs and joint ventures.
In 1999 he joined Life Science Ventures, Munich,
to advise the Global Life Science LP. He is on the Board of several
portfolio companies. He is a Partner in GLSV II, a fund being raised
in 2001.
back
to top
|
 |
|
| |
|
Nick Lowcock, Managing Director, European
Healthcare,
E.M. Warburg, Pincus & Co. International, Ltd.
Mr Lowcock, age 37, has been with Warburg Pincus since 1994. Prior
to joining Warburg Pincus he was with the Boston Consulting Group
and previously worked in the pharmaceutical industry in the United
Kingdom. He is a Director of The Medicines Company Inc., Eurand
Pharmaceutical Holdings, B.V., Leciva Pharmaceutical Holdings B.V.,
Strakan Group Plc., Craegmoor Healthcare Ltd., Pharmaidea B.V. and
Aspect Holdings Ltd. Mr Lowcock is also on the board of Project
Hope U.K.., a charity devoted to improving healthcare in developing
nations.
back
to top
|
 |
|
| |
|
Dr. Dalia Megiddo, MBA, Managing Partner
of Innomed Ventures,
Jerusalem Global ventures - Innomed
Dr. Dalia Megiddo is the Managing Partner of InnoMed, Jerusalem
Global Ventures’ fund for the Life Sciences. Since 1994 she
has also edited and produced Academia Medica, a multimedia medical
teaching program and produces and the highly successful Israeli
medical audio magazine The Journal Club. Dalia completed her residency
in family medicine at Hebrew University and was on staff at the
Hebrew University-Hadassah Medical Health Center from 1985-86.
Dalia's work has garnered both national and
international recognition, including the Annual Award of the Israel
Gerontology Society for her publication of "Domestic Care Dependency
in the Aged" in 1985; a Merit of Excellence Award in the annual
Israel Prime Minister's Software Competition in 1997; and the US
Apple Gold Award for Education Media in 1998.
Dalia has authored several articles in Israeli
and international medical journals. She has served as a presenter
at worldwide medical conferences, including the World Conference
on Family Medicine, the AAFP 47th Annual Scientific Assembly, the
Third European Congress on Family Medicine and the Radiological
Society of North America
back
to top
|
 |
|
| |
|
Dr Juerg Meier, Executive Director,
Novartis Venture Fund
Since 1998 Juerg Meier, Dr. sc.techn.ETH, is the Executive Director
of the Novartis Venture Fund. Previously, he worked for over 25
years in various international functions for Sandoz Pharma Ltd.:
as Head Research & Development of Biochemie Ges.m.b.H. in Austria;
Head of Research & Development in the US, Head of Research & Development
Sandoz Pharma worldwide and President of Sandoz Pharma Japan.
back
to top
|
 |
|
| |
|
Dr. Holger N Mueller, Investment Director,
3i Deutschland
Dr. Holger Mueller is investment director with 3i Germany and head
of the Munich healthcare team. He joined Technologieholding VC in
1997 as Investment Manager responsible for healthcare investments.
Before he was Product manager with Biometra/Whatman. He holds a
Ph.D. in Biochemistry and a diploma degree in molecular biology.
back
to top
|
 |
|
| |
|
Dr. Jörg Neermann, Senior Partner,
DVC Deutsche Venture Capital
Jörg works as a venture capitalist specializing
in the Life Science arena since 1996. Prior to joining DVC in 1998
as an investment manager he worked in the international Life Science
team of Atlas Venture. Jörg holds an M.S. and Ph.D. degree
with 'summa cum laude' in Biotechnology which he studie at TU Braunschweig,
Germany, and M.I.T., Cambridge, USA. He also studied economics at
Harvard Business School and TU Braunschweig. During his Ph.D. at
the GBF German National Research Institute for Biotechnology) he
also worked at a mid-sized top-tier management consulting firm.
Jörg became a partner with DVC in 2000 and Senior Partner in
2001. He is a member of the supervisory board of the following companies:
Epigenomics AG (Chairman) • 4SC AG • Switch Biotech AG
• Biopsytec AG • G2M AG • DeveloGen AG (observatory
seat)
back
to top
|
 |
|
| |
|
Philip Rattle, Director,
JPMorgan Partners
Prior to joining JPMP in January 1998, Philip Rattle worked for
eight years in the Venture Capital industry with 3i plc, most recently
as Investment Director in London. There he was responsible for a
wide range of MBO and venture investments with a particular focus
on technology and healthcare. He holds a BA (Hons) from Oxford University.
back
to top
|
 |
|
| |
|
Professor Stephen K. Smith, Head of
Department, Obstetrics & Gynaecology,
University of Cambridge
Professor Stephen Smith was appointed Head of the Department of
Obstetrics and Gynaecology at the University of Cambridge in 1988
and he is Head of Service for Women’s Health at Addenbrooke’s
Hospital. Professor Smith is a Fellow of the Academy of Medical
Sciences, a Fellow of the Royal College of Obstetricians and Gynaecologists,
a Fellow of the Institute of Biology and a member of many learned
societies and editorial board member of numerous international scientific
journals. Professor Smith is a leading expert on the subject of
angiogenesis in the female reproductive tract and is currently studying
the way in which multiple gene expressions regulate vascular structure
in the endometrium.
back
to top
|
 |
|
| |
|
Dr. Jeff Solomon, Chief Executive,
ERBI, UK
Jeff graduated from London University with a Ph.D. in biochemical
engineering and has 16 years experience working with a number of
organizations within the healthcare and life science sectors undertaking
and managing manufacturing R&D and developing strategy. He joined
the ERBI initiative and focused its efforts on the development of
networking and communications within the Cambridge and East of England
bio-community. In April 2000 ERBI became an independent not for
profit company limited by guarantee and Jeff became its full time
Chief Executive.
back
to top
|
 |
|
| |
|
Mr. Otello Stampacchia, Vice President
of Immunology,
Lombard Odier & Cie
Born in Italy in 1969, Otello studied genetics in the University
of Pavia, Italy, from 1987 till his Master in Genetics in 1991,
Magna cum Laude, with a research thesis on plant genetic engineering.
He continued his studies till obtaining a Ph.D. in Molecular Biology
from the University of Geneva in 1997.
During 1997, Otello also acted as a consultant for biotechnology
investments to Index Ventures, a venture capital firm based in Geneva,
directing their biotechnology practice. Following his Ph.D. thesis,
Otello moved to Goldman Sachs in London, where he worked in the
Corporate Finance/Mergers and Acquisition practice for health care
and biotechnology clients.
Otello joined Lombard Odier in February 2001 as Manager for the
Lombard Odier Immunology Fund in the AM&R division, focusing
on small cap and private biotechnology investments.
back
to top
|
 |
|
| |
|
Dr. Eric Tambuyzer, Chairman EuropaBio Board
of Management, Vice President, Corporate Affairs
GENZYME Corporation
Dr. Tambuyzer joined Genzyme Corporation (Cambridge, MA,
USA - Leuven, Belgium) in 1992. Currently, Dr. Tambuyzer is Genzyme
Corporation’s Vice President, Corporate Affairs, Europe, and
a Member of the European Executive Board. Starting his professional
career at Baxter Health Care (Baxter-Travenol, Brussels) in 1977,
he pursued his career at Innovi NV (Brussels), as a consultant to
industry in technology transfer from academia. He co-founded the
biotechnology company Innogenetics NV (Ghent, Belgium) in 1985,
of which he remained General Manager until 1992.
In October 2000, Dr. Tambuyzer was elected Chairman
of the Board of EuropaBio, the European Association for Bioindustries,
of which he is also the Founder & Chairman of the Ethics Committee.
Dr. Tambuyzer is also a Board Member of the European Platform for
Patients’ Organizations, Science & Industry, EPPOSI, and
of EBE, the Emerging Biopharmaceuticals Enterprises group, a specialised
group within EFPIA, the European Pharmaceutical Industry Association.
He is an adviser to several international journals and since 2001
he serves as Chairman of the Advisory Board to Dresdner Kleinwort
Capital's global life sciences fund.
Dr. Tambuyzer is a bio-engineer and holds a doctoral
degree in bio-industrial sciences from the University of Leuven,
(KUL), Belgium. A Belgian citizen, born in 1949, he is married and
has 3 children.
back
to top
|
 |
|
| |
|
Claudio Werder, First Vice President,
Head of Life Sciences Team,
Bank Vontobel AG
Claudio Werder is head of Bank Vontobel's European Life
Sciences Research Team. He has been working for more than 20 years
as pharmaceuticals and medtech analyst and has been involved in
the public offerings of Sulzer Medica, Ciba Specialty Chemicals,
Biomarin, MediGene and Modex as well as in the private placement
of Centaur Pharmaceuticals Inc. Claudio Werder holds a MBA (lic.oec.publ.)
of the University of Zurich.
back
to top
|
 |
|
| |
|
Robert Wyss, Head SWX New Market,
SWX Swiss Exchange
After graduating as BBA from University of Berne, head of the research
team for the Swiss stock market at Zürcher Kantonalbank in
Zürich (1987 – 1994). Berner Kantonalbank, Bern: responsible
for consulting and portfolio management for institutional investors
(1994 – 1997). From 1997 to 1998 responsible for investment
strategy and portfolio management at the Private Bank Von Graffenried
in Berne. Evaluation of venture projects for Berne Venture Ltd.
Since June 1998 head of Key Account Issuers and responsible for
the SWX New Market at the SWX Swiss Exchange.
back
to top
|
 |
|
| |
|
Stan Yakatan, Chairman,
Katan Associates
Mr Stan
Yakatan has founded and co-founded nine companies; served as Chairman,
CEO or President of seven companies; raised in excess of $200 million
through both public and private financing; and currently serves
on a number of corporate boards. Mr Yakatan has served in senior
management positions with New England Nuclear (a Division of E.I.
Dupont) and ICN Pharmaceuticals where he was responsible for strategy
related to their biotechnology business areas as well as having
full profit and loss responsibility. He has also completed numerous
acquisitions and licensing deals in the biopharmaceutical marketplace.
back
to top
|
 |
|
| |
|
Robert Zegelaar, Principal,
Atlas Venture
Robert Zegelaar joined Atlas Venture in 1987. With a Master of Science
degree in Business Administration from the University of Groningen,
Rob concentrates on investments in healthcare. Board participation
includes:
CropDesign NV, eLabsEurope AG, Glaucus Proteomics BV, Impella Cardiotechnik
AG, IsoTis NV, Micromet AG, Renovo, Ltd
back
to top
|
 |
|
| |
|
Prof. Dr. Jesper Zeuthen, Managing
Director, Professor, Dr. Sc
BankInvest Bio Venture
Jesper Zeuthen has been working for the BankInvest Group as a consultant
since 1988, and he decided to join us full time in spring 2000 working
primarily with venture capital. Previously, Jesper Zeuthen has worked
as Head of R & D at Novo Nordisk and Head of Research at The
Danish Cancer Society. He is the author of more than 200 publications
in immunology, cell biology and molecular biology and served as
adjunct professor of biotechnology at the University of Copenhagen.
back
to top
|
 |
|
| |